BEIJING (dpa-AFX) - Sinovac Biotech Ltd. (SVA) Monday said it has initiated Phase 2 trial of its SA55 injection, intended for the treatment of Covid-19.
The Phase 1 study, which was completed recently, had confirmed the preliminary safety profile of SA55 in 40 healthy adults aged 18 to 65 in China.
Phase 2 study will evaluate the ability of SA55 to reduce SARS-CoV-2 viral load and alleviate clinical symptoms in nearly 150 patients to be enrolled with mild to moderate Covid-19. Preliminary results are expected by the year-end.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX